Clinical Trials Logo

Hyperparathyroidism clinical trials

View clinical trials related to Hyperparathyroidism.

Filter by:

NCT ID: NCT00211939 Completed - Arteriosclerosis Clinical Trials

CARE-2 (Calcium Acetate [PhosLo®]/Sevelamer[Renagel®] Evaluation Study 2) for Heart Calcification in Dialysis Patients

Start date: January 2005
Phase: Phase 4
Study type: Interventional

The purpose of the study is to evaluate the effects of two phosphate binders, PhosLo and sevelamer, on heart calcification in dialysis patients. The study will use a non-invasive technique, electron beam computed tomography (CT) scanning, to measure calcium in the coronary arteries, the aortic valve, and the mitral valve.

NCT ID: NCT00189501 Completed - Nephrology Clinical Trials

A Multi-Center, Observational Registry of Subjects With Secondary Hyperparathyroidism (HPT) and Chronic Kidney Disease (CKD)

Start date: December 2004
Phase: N/A
Study type: Observational

Objectives include description of current practices; assessment over time of K/DOQI goals, clinical outcomes, health resource utilization(HRU) and patient reported outcomes (PRO) and the impact of Sensipar® on these parameters

NCT ID: NCT00135304 Completed - Clinical trials for Secondary Hyperparathyroidism

ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism

Start date: August 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.

NCT ID: NCT00132431 Completed - Clinical trials for Chronic Kidney Disease

START: Sensipar Treatment Algorithm to Reach K/DOQI Targets in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism

Start date: July 2004
Phase: Phase 4
Study type: Interventional

The purpose of this research is to study the effects and safety of Sensipar approved by the Food and Drug Administration (FDA) in patients with kidney failure who are being treated with dialysis and have uncontrolled secondary hyperparathyroidism (HPT).

NCT ID: NCT00123461 Completed - Renal Failure Clinical Trials

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Start date: July 2005
Phase: Phase 4
Study type: Interventional

The purpose of this study is to demonstrate the safety and effectiveness of Hectorol® (doxercalciferol) capsules in treating patients with Stage 3 or Stage 4 chronic kidney disease (CKD) with secondary hyperparathyroidism who have vitamin D levels in the normal range. Previous studies with doxercalciferol were conducted in patients who had low levels of vitamin D.

NCT ID: NCT00117052 Completed - Clinical trials for End Stage Renal Disease

SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

Start date: September 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate that the efficacy of cinacalcet when co-administered with the first meal after dialysis is comparable (non-inferior) to the efficacy of cinacalcet when administered during the dialysis study visit.

NCT ID: NCT00110929 Completed - Clinical trials for End Stage Renal Disease

Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)

Start date: November 2002
Phase: Phase 2
Study type: Interventional

The purpose of this research is to study the efficacy and safety of AMG 073 in patients with kidney failure who are being treated with hemodialysis or peritoneal dialysis and who also have secondary hyperparathyroidism (HPT).

NCT ID: NCT00094484 Completed - Clinical trials for Chronic Kidney Disease

Cinacalcet HCl in Chronic Kidney Disease Subjects With Secondary Hyperparathyroidism Not Receiving Dialysis

Start date: October 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of cinacalcet compared with placebo in patients with stage 3 and 4 Chronic Kidney Disease (CKD).

NCT ID: NCT00073710 Completed - Clinical trials for Chronic Kidney Disease

Study to Evaluate the Effects of Zemplar Injection and Calcijex on Intestinal Absorption of Calcium

Start date: September 2004
Phase: Phase 4
Study type: Interventional

A study to investigate the effects of Zemplar and Calcijex on intestinal calcium absorption in hemodialysis subjects.

NCT ID: NCT00053547 Completed - Clinical trials for End Stage Renal Disease

Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis

Start date: January 2002
Phase: Phase 4
Study type: Interventional

The purpose of this study is to see if Zemplar, a vitamin D medication, safely and effectively decreases parathyroid hormone in children ages 2-20 with End Stage Renal Disease.